Spots Global Cancer Trial Database for MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Official Title: Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Study ID: NCT03916679
Conditions
Interventions
Study Description
Brief Summary: The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory epithelial ovarian cancer.
Detailed Description: Primary Objectives To determine the feasibility ad safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer. Secondary Objectives To access the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact Details
Name: Jianwei Zhou, M.D.
Affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
